P2.03a-046 Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
نویسندگان
چکیده
منابع مشابه
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
BACKGROUND This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial. PATIENTS AND METHODS Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m(2) weekly (nab-P/C) or solvent...
متن کاملA retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
PURPOSE The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monoth...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Efficacy and Safety of Everolimus in Elderly Patients with mRCC
1Department of Urology, Osaka Medical College, Takatsuki, 2Department of Urology, Osaka University, Graduate School of Medicine, Suita, 4Department of Urology, Kansai Medical University, Hirakata, 5Department of Urology, Kinki University School of Medicine, Osaka-Sayama, 6Chiba Cancer Center, Chiba, 8Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate Sc...
متن کاملNab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old
Introduction: Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patient...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1256